Research
Nrf2 inhibition overcomes regorafenib resistance in well-differentiated sorafenib-resistant hepatocellular carcinoma cells
Nature ·
The Brief
- The study reports that Nrf2 inhibition overcame regorafenib resistance in well-differentiated sorafenib-resistant hepatocellular carcinoma cells.
- No summary was provided, so these points rest on the article title alone.
Why it matters
Drug resistance is a central obstacle in cancer treatment research, so a way to overcome resistance in liver cancer cells is relevant to researchers in this field.
Who’s affected
- researchers studying liver cancer and drug resistance
- #liver cancer
- #drug resistance
- #nrf2
- #regorafenib
- #hepatocellular carcinoma